Free Daily Podcast Summary
The Genetics Podcast: Daily Summaries Delivered
by Sano Genetics
Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 3 days ago39 min
EP 257: Managing hereditary cancer risk and medical uncertainty with Marleah Dean Kruzel of the University of South Florida
This week on The Genetics Podcast, Patrick is joined by Dr. Marleah Dean Kruzel, Professor of Communication at the University of South Florida. They discuss her personal path from watching breast cancer move through her family to testing positive for a hereditary mutation herself, the ART framework she developed for managing uncertainty, and the complexities of communicating genetic risk within families.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Marleah01:35 Marleah's family history of breast cancer across four generations02:48 Marleah's childhood living through her mother's five-year cancer battle04:26 Marleah's experience with genetic testing07:19 How a positive test result reshaped Marleah’s PhD research focus08:40 The central challenges of living with a positive test result 10:50 The ART framework for managing hereditary cancer uncertainty15:06 Applying the ART framework to Patrick’s experience with uncertainty and the importance of having a support system 19:53 Common misconceptions in how families communicate genetic risk23:54 The previvor identity and the chronic uncertainty it brings25:40 How Marleah has learned to accept and embrace uncertainty27:57 Balancing logic and emotion in hereditary cancer family planning31:28 How Marleah grounds her research tools in patients' lived experience33:21 How AI is eroding our capacity to sit with uncertainty35:57 Redesigning healthcare for a lifespan of genetic risk information38:10 Closing remarks
- 1 weeks ago40 min
EP 256: Cutting through the AI hype in drug discovery with Dave Hallett of Recursion
This week on The Genetics Podcast, Patrick is joined by Dr. David Hallett, Chief Scientific Officer at Recursion. They discuss the biggest shifts in drug discovery over Dave's three-decade career, where AI is genuinely transforming the field today versus where the hype outruns the reality, and how Recursion's perturbational maps have uncovered and validated a novel neurodegeneration target.Show Notes0:00 Intro to The Genetics Podcast01:00 Welcome to Dave01:57 The biggest shifts in drug discovery over three decades06:39 Where AI is delivering real wins across drug discovery today12:19 How AI-assisted trial simulation reveals which eligibility criteria to relax14:46 The three biggest reasons drug programs fail in the clinic 18:20 How Recursion's perturbational maps uncover new drug targets24:58 A four-step framework for validating a novel drug target28:44 How Recursion balances deep therapeutic focus with partnership breadth30:52 Why AI can't shortcut clinical trials, and what proof of real impact looks like34:57 The skills scientists need most in the AI era, and why trusting AI outputs starts with trusting the data39:52 Closing remarksFind out more:Recursion (https://www.recursion.com/)
- 2 weeks ago36 min
EP 255: Turning long-read sequencing into a routine part of clinical care with Danny Miller of the University of Washington
This week on The Genetics Podcast, Patrick is joined by Dr. Danny Miller, Assistant Professor of Pediatrics and of Laboratory Medicine and Pathology at the University of Washington and Attending Physician at Seattle Children's Hospital. They discuss the case for making long-read sequencing the first genetic test every patient receives, the reference dataset his lab is building from the 1000 Genomes Project to resolve structural variants, publicly available methylation signatures as biomarkers for diagnosis and treatment response, and his vision for genome-informed care from newborn screening through the NICU.Show Notes0:00 Intro to The Genetics Podcast01:00 Welcome to Danny01:41 The case for long-read sequencing as first-line genetic testing02:52 Current barriers to wider use of long-read sequencing 04:14 Building a long-read reference dataset from 1000 Genomes for variant filtering06:47 How long-read sequencing can solve a missed diagnosis 08:12 The clinical case for complete telomere-to-telomere genomes10:39 What it will take to shift the clinical genetics status quo12:06 Making methylation signatures public to diagnose disease and track therapy15:58 Danny's path from programming and finance into clinical genetics18:19 Danny's lived experience with deafness and achondroplasia, and how it shapes his approach to genetic counseling21:46 Danny's optimism about AI in genomics and worry about AI in education27:15 The path to making genomes a routine part of the medical record29:47 The vision of same-day newborn genomic data guiding NICU treatment decisions34:31 Closing remarksFind out more:Miller Lab (https://millerlaboratory.com/)
- 3 weeks ago41 min
EP 254: Triangulating genetic evidence and dodging bias to pick winning drug targets with Brent Richards of 5 Prime Sciences
This week on The Genetics Podcast, Patrick is joined by Dr. Brent Richards, CEO and Founder of 5 Prime Sciences and Professor of Human Genetics, Epidemiology, and Medicine at McGill University. They discuss how to triangulate different types of genetic evidence to validate a drug target, why herd psychology often drives which targets get funded, why strong genetic support didn't save the Zeus IL-6 trial, and how collider bias can distort genetically stratified clinical trials.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Brent01:43 How company size shapes access to genetic drug discovery tools04:10 Brent's framework for triangulating different types of genetic evidence06:50 The herd psychology behind which drug targets get funded10:01 Potential reasons the Zeus IL-6 trial failed despite strong genetic evidence12:49 What a gold standard genetic evidence package actually looks like 17:13 Closing the data gap with diverse genomes and systematic pipelines19:03 The diabetes patient story that drove Brent into drug development and balancing academia with industry25:39 Why obesity went from a drug development graveyard to its biggest frontier29:13 How collider bias can distort genetic risk trial results38:20 Where to go deeper on advanced genetic drug discovery concepts40:11 Closing remarksFind out more:5PrimeSciences’ symposium on human genetics at ASHG2026 in October
- Aug 20, 202637 min
EP 253: The genetics of brain size, growth, and aging with Andrew Jackson of the University of Edinburgh
This week on The Genetics Podcast, Patrick is joined by Dr. Andrew Jackson, Programme Leader at the MRC Human Genetics Unit at the University of Edinburgh. They discuss how his lab discovered that gain-of-function DNMT3A mutations cause both microcephalic dwarfism and an accelerated aging syndrome, and what that reveals about the shared biology of growth and aging.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Andrew01:34 The origins of Andrew's work linking brain size and aging02:54 The genetics of mammalian size range and epigenetic factors regulating growth05:02 How DNMT3A mutations causing dwarfism led to discovering an accelerated aging syndrome09:46 Cell number rather than cell size as the shared driver of growth and aging13:07 Whether brain size within humans actually predicts cognitive ability15:20 Why intellectual disability has far more known genes than dwarfism19:26 Discovering ribonuclease H2's role in DNA repair, and its unexpected link to cancer 23:35 Why studying rare monogenic diseases reveals broader biology26:59 Andrew's next research questions on aging, cancer, and mutation biology28:42 Why humans, model organisms, and cell assays each have a role31:00 Somatic mosaicism's growing role in aging and disease beyond cancer36:11 Closing remarksFind out more:Mentioned studies from Andrew’s lab: https://www.nature.com/articles/s41588-026-02633-8https://www.nature.com/articles/s41588-018-0274-x
- Aug 13, 202637 min
EP 252: The diagnosis that became a mission to cure rare disease: Advancing genetic medicine using AI with Stevie Ringel of Nome
This week on The Genetics Podcast, Patrick is joined by Stevie Ringel, co-founder of Nome and founder of the Kizuna Foundation. They discuss Stevie's own ultra-rare disease diagnosis and shaped his path to founding Kizuna Foundation and Nome, how Nome's AI agents help scientists navigate the operational complexity of small-batch drug development, the technical and business model advantages underpinning Nome's accuracy, and what it will take to build a sustainable funding model for ultra-rare disease.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Stevie01:37 Stevie's inherited retinal disease (IRD) diagnosis and subsequent path into genomics03:16 Why Stevie founded Kizuna Foundation and why ultra-rare drug development is so operationally complex06:27 The origin story of Nome and using AI to automate the operational work 10:09 The inspiration for the name “Nome” and who the company is built to serve12:44 The biggest blockers to program speed15:07 How AI and scale can bring down the cost of gene therapy manufacturing18:01 FDA signals and global regulatory competition 19:33 Priority review vouchers and why Nome stays out of molecule IP20:33 Nome's AI and review process for patient reports and its expansion to health systems25:04 Nome's agent architecture and the data behind its accuracy28:17 Why delivery remains gene therapy's biggest bottleneck and approaches for solving it31:34 The case for a new capital model in rare disease drug development 33:25 What’s next for Nome as they advance preclinical programs34:25 Nome’s focus on process excellence across therapeutic modalities36:34 Closing remarksFind out more: Nome
- Aug 6, 202638 min
EP 251: Cracking the delivery barrier in genetic medicine with Jagesh Shah of Mirai Bio
This week on The Genetics Podcast, Patrick is joined by Dr. Jagesh Shah, Chief Scientific Officer at Mirai Bio. They discuss why delivery is a central bottleneck holding back nucleic acid medicines, how Mirai's lipid nanoparticle (LNP) platform is built to reach tissues like adipocytes and T cells, and the machine learning feedback loop the company uses to engineer LNP formulations.Show Notes0:00 Intro to The Genetics Podcast01:00 Welcome to Jagesh01:40 Why delivery is the main bottleneck for gene therapies03:42 Easier vs harder tissues to target for delivery06:40 Overview of Mirai's modular delivery platform 09:02 Comparing viral vectors and lipid nanoparticles (LNPs) 12:18 Different approaches for targeting adipocytes and T cells with LNPs15:49 Mirai's machine learning (ML) feedback loop for optimizing LNP formulation20:50 Why lipid chemistry is still hard for ML to learn and factors affecting LNP tropism24:35 Jagesh's path from academia to Mirai27:23 Mirai's platform business model and how it lowers risk29:13 What industry partnerships with Mirai look like31:41 Mirai's next frontier of delivery to muscle tissue and the brain 34:40 Cargo size and immunogenicity of LNPs vs AAV 36:00 Why the field needs to close the regulatory pace gap 37:19 Closing remarksFind out more:Mirai Bio
- Jul 30, 202641 min
EP 250: Redefining rare disease realities with Sharon Terry of the Genetic Alliance [Re-run]
This week on The Genetics Podcast, Patrick is joined by Sharon Terry, President & CEO of Genetic Alliance. They discuss how Sharon established a layperson-led biobank, her long-term work on rare diseases and patient advocacy, and her program to bring genetic technology to patients in low- to middle-income countries. We’re re-running this episode for its enduring lessons on patient advocacy, rare disease parenting, communication, and citizen science. Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Sharon and a discussion of the personal experience with rare disease that started her journey03:47 Reasons Sharon decided to establish the first layperson-led biobank05:34 Challenges with setting up the biobank infrastructure07:00 Balancing financial factors in a non-profit organization 09:30 Recent patterns and future insight into rare disease drug discovery framework and regulation15:32 Barriers to widespread collaboration and cooperation in rare disease research, and why it should be approached from a public health perspective18:12 Background and experiences from the iHope Genetic Health program in low- to middle-income countries24:44 Sharon’s perspective on challenges with the Genetic Information Non-discrimination Act28:49 Sharon’s lessons learned in her patient advocacy and policy work, and her hopes for future legislation33:04 Sharon’s hopes for improved access to genetic testing and treatment for children in underserved communities34:34 How Sharon learned about rare diseases and genetics as a “homeschooling mom without a degree”37:54 Insights into how elements of spirituality can support advocacy work40:18 Closing remarks
Get The Genetics Podcast summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Genetics Unzipped
Explores stories from the world of genetics, from Mendel's experiments to modern genome research.
Plenary Session
A medical oncologist discusses cancer care, health policy, and evidence-based medicine.
Chasing Life with Dr. Sanjay Gupta
A doctor investigates global lifestyles linked to longevity, brain health, and aging well to understand how people live happier, healthier lives.
The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.
Huberman Lab
Explores neuroscience and science-based tools for understanding and improving brain function, behavior, and health.
Science Magazine Podcast
Weekly episodes covering original scientific research, global science news, and expert commentary.
Stanford Psychology Podcast
Students interview psychologists about recent research and its real-world applications in mental health, behavior, and cognition.
Paul Saladino MD podcast
A physician explores the root causes of chronic disease and optimal health through science and personal experimentation.
Unbiased Science
Two scientists analyze health topics using objective, evidence-based approaches to inform everyday decisions.
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
ON CRISPR: The Story of Jennifer Doudna with Walter Isaacson
A Nobel-winning biochemist pioneers CRISPR gene editing, sparking scientific breakthroughs, global competition, and ethical debates.
Data & Science with Glen Wright Colopy
Discusses healthcare technology with experts, focusing on data science and engineering innovations in clinical applications.
About The Genetics Podcast
Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Genetics Podcast in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Genetics Podcast daily summary?
It's a free AI-powered email that summarizes new episodes of The Genetics Podcast as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Genetics Podcast podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Genetics Podcast product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Sano Genetics.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Genetics Podcast release new episodes?
The Genetics Podcast publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Genetics Podcast cover?
The Genetics Podcast covers topics including Science, Natural Sciences, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Genetics Podcast summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.